XTL Biopharmaceuticals' ADRs Commence Trading on NASDAQ Stock Market
HERZLIYA, Israel, July 15, 2013 /PRNewswire/ --
XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL) (the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs, today announced that its ADRs began trading on NASDAQ today, July 15, 2013 under the ticker symbol "XTLB".
The Company's ADRs are Level II ADRs, each representing 20 ordinary shares in the Company.
About XTL Biopharmaceuticals Ltd. ("XTL")
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.
XTL's lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world for the treatment of severe anemia.
XTL holds more than 30% in Proteologics Ltd. (TASE: PRTL), a drug discovery company, and controls InterCure Ltd. (TASE: INCR), a company which has disrupted the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (http://www.resperate.com).
XTL is a public company traded on The NASDAQ Stock Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv MidCap-50, Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
SOURCE XTL Biopharmaceuticals Ltd
More by this Source
XTL Biopharmaceuticals Returns to NASDAQ
Jul 10, 2013, 13:45 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.